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Abstract 
Lung cancer (LC) is the most common cancer worldwide, affecting over a million people 
every year. It is the leading cause of cancer-related death in the world, and the diagnosis of 
this disease is usually associated with poor prognosis. In Palestine, according to the 
Palestinian Cancer Registry (PCR), lung cancer has been considered the fourth common 
cancer morbidity in the general population, and considered the first common cancer 
mortality in the general population. 
Activation induced cytidine deaminase (AID), a member of the cytidine deaminase family, 
is expressed in activated B cells and is involved in antibody diversification by inducing the 
mutations of immunoglobulin genes. The role of AID in immune response is essential for 
somatic hypermutation & class switch recombination in B lymphocytes. Although the 
primary and physiologically relevant targets for AID are immunoglobulins, AID has been 
shown to attack non-immunoglobulin genes and induce mutations broadly throughout the 
genome. This property of AID; acting as a DNA mutator, is considered a double edge 
sword in cellular metabolism. Several studies have shown that AID expression is associated 
with non-Hodgkin lymphoma and follicular lymphoma as well as non lymphoid cancers 
such as gastric cancer, hepatocellular carcinoma, and ulcerative colitis-associated 
carcinoma. 
The aim of this study is to investigate the expression levels of AID protein in several types 
of LC in Palestinian patients, to check if AID is aberrantly expressed in these types. To 
achieve this aim, parrafin blocks of 63 LC cases with their clinico-pathological data, were 
collected retrospectively (from 2000-2011) from patients' medical files from the pathology 
department of Al-Maqassed hospital. And the expression levels of AID were examined in 
all these cases by immunohistochemistry (IHC) analysis. 
Aberrant AID protein expression was detected in 22.2% (13 of 58) of the LC cases. The 
results showed that AID protein was expressed in 18% (10 of 50) of non-small cell lung 
carcinoma (NSCLC) and 100% (3 of 3) of small cell lung carcinoma (SCLC). Moreover 
23% (7 of 31) of squamous cell carcinoma and 13% (3 of 24) of adenocarcinoma express 
AID protein. No correlation was detected between AID protein expression and clinic-
pathological data of the patients such as gender, age, LC type, tumor grade. In conclusion, 
examination of AID protein expression in LC revealed aberrant expression of AID protein 
in a subset of LC Palestinian patients. 
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Chapter One: Introduction 
1.1. Lung Cancer: 
Lung Cancer (LC) like other types of cancer is a multistage process involving alterations in 
multiple genes and diverse pathways (Devereux et al., 1996). These mutations can cause 
activation of cancer promoting genes (oncogenes) or switching off cancer protecting genes 
(tumor suppressors). Several mutations in different genes may be required to turn a normal 
cell into a cancerous one. At first the changes to a cell may be reversible but as more 
mutations accumulate, the changes become irreversible and a cancerous cell develops 
(Collins et al., 2007; Gilligan and Rintoul, 2007). The two major types of LC are non-small 
cell lung cancer NSCLC (about 80% of LC) and small cell lung cancers SCLC (about 
20%). The tumor starts off in the lungs and although, initially, it may be limited to one 
lung, it will eventually spread to other parts of the body (Gilligan and Rintoul, 2007).  
 
1.1.1. Epidemiology of Lung Cancer:  
According to the Palestinian Cancer Registry (PCR), the most common cancer morbidity 
in the general population was breast (15.7%), lymphomas (9.1%), bone marrow (9.1%), 
bronchus and lung (8.7%), colorectal (7.4%), brain and other nervous system (4.8%), 
urinary bladder (4.7%), stomach (3.5%), liver (3.3%), and prostate (2.9%). In males, 
bronchus and lung cancer was the first leading cause of cancer morbidity (14.7%). In 
females, breast cancer (30%) was the first cause of morbidity (Abdeen, 2006). 
 
As for mortality rates, the most common cancer mortality in the general population was 
bronchus and lung (12.7%), breast (11.1%), bone marrow (9.9%), lymphomas (7.2%), 
colorectal (7.1%), urinary bladder (3.9%), liver (5.2%), stomach (4.2%), brain and other 
nervous system (5.8%) and pancreas (3.8%). In males, bronchus and lung cancer was the 
first leading cause of cancer mortality (19.9%), and breast cancer (23.1%) was the first 
 2
cause of mortality in females. Median age at death for all cancer types was 59 years (63 
years for male and 54 year for female) (Abdeen, 2006; MOH, 2002).  
 In Gaza, the incidence rate of breast cancer is 60 per 100,000 population making it the 
most prevalent type of cancer (16.4%) in the total population according to Cancer Registry 
Center. Lung cancer was the most prevalent type of males' cancer (12.7%), while breast 
cancer occupied the most prevalent type in females (31%) (Abdeen, 2006; MOH, 2002). 
  
1.1.2. Risk Factors of Lung Cancer:  
LC represents the prototype of a cancer induced by chemical and environmental 
carcinogens. Smoking is the major risk factor of LC, accounting for about 90% of LC 
incidence (Biesalski et al., 1998). Several exogenous and endogenous risk factors have 
been shown to contribute to LC development. Although LC can occur at any age, the risk 
of developing LC increases with age. Lung cancer is uncommon under the age of 50 years 
and three quarters of causes occur over the age of 63 years old (Gilligan and Rintoul , 
2007).  
Smoking causes the vast majority of the cases of LC. About nine out of ten people who 
develop LC are, or have been smokers. Passive smoking (environmental tobacco smoke) is 
also considered as a human carcinogen. A non-smoker who is married to a smoker has up 
to a 30% greater risk of developing LC compared to someone who is married to a non-
smoker. Exposure to non-tobacco carcinogens such as radon, asbestos, and chemical 
carcinogens such as diesel fumes, uranium, nickel, arsenic, zinc, polycyclic hydrocarbons, 
and chromium, stimulate LC (Gilligan and Rintoul, 2007; Biesalski et al., 1998). 
There is some evidence that people who has had previous radiotherapy to their chest or for 
Hodgkin's disease may be at increased risk of LC, especially if they smoke, or have other 
risk factors. People who have scarring within their lungs from other causes, e.g. Lung 
fibrosis, seem to be particularly prone to developing LC especially if they also smoke 
(Gilligan and Rintoul, 2007). Brothers, sisters and children of those who have had LC may 
be at a slightly higher risk of developing LC themselves (Collins et al., 2007). 
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1.1.3. Types of Lung Cancer:  
Around 95% of primary LC is epithelial in origin, and these are categorized on the basis of 
histological appearance into; NSCLC and SCLC (Hirsch et al., 2001). NSCLC accounts for 
about 80% of cases of LC, and SCLC for the remaining 20%. Both types usually behave 
differently and respond to treatment differently (Herbst et al., 2008; Gilligan and Rintoul, 
2007). 
NSCLC: 
NSCLC is usually divided into three different types depending on its appearance under the 
microscope squamous cell carcinoma, adenocarcinoma, large cell carcinoma.  Squamous 
cell carcinoma is the most common type of NSCLC. This type tends to grow more slowly 
than the other types of LC and spreads at a later stage. Adenocarcinoma can spread to the 
lymph glands or to other parts of the body at an early stage, it is the most common type to 
occur in people who have never smoked. Large cell carcinoma accounts for about 10% of 
all lung cancers. and found in smokers, it has high tendency to spread to lymph nodes 
(Gilligan and Rintoul, 2007; Travis, 2002; Herbst et al., 2008 ). 
 
SCLC: 
SCLC as the name implies, the cells of this type appear small under the microscope and are 
largely filled by the nucleus. Small cell carcinoma can occur in any organ but the great 
majority develops in the lung (Terada, 2012).  Almost all SCLC cases are caused by 
smoking; it is rare for someone who has never smoked to develop it. It is an aggressive 
type of LC and in the majority of cases it spreads to the lymph glands or to other parts of 
the body by the time it is discovered (Gilligan and Rintoul, 2007).  
 
Other types of LC include hamartoma and carcinoid tumors. Hamartomas are the most 
common type of benign (non-cancerous) lung tumor. They are usually quite small, and 
mostly cause no symptoms. They never become cancerous or reoccur following removal 
(Gilligan and Rintoul, 2007).  
Carcinoid tumors are a rare form of tumor that can occur in various parts of the body 
including the lung. They belong to the family of neuroendocrine tumors (Gilligan and 
Rintoul, 2007). The symptoms that they cause tend to depend on their location within the 
lung (Gilligan and Rintoul, 2007). 
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1.1.4. Symptoms of LC: 
The most common symptoms that can occur in the late stage LC include; persistent cough, 
shortness of breath, coughing up blood (haemoptysis), repeated chest infections that are 
slow to clear up, tiredness and fatigue, noisy breathing, horse voice, unexplained weight 
loss, and new aches or pains in the chest or shoulders (Gilligan and Rintoul, 2007). 
1.1.5. Staging of Lung Cancer: 
The accurate staging of LC provides both prognostic information and appropriate treatment 
to the patients. Once a LC has been diagnosed, it is important to know exactly which part 
of the lung it is laying in, how big it is, and whether it has spread in order to know the 
cancer's stage and the appropriate treatment. The staging systems used for NSCLC and 
SCLC are different. The international classification system for NSCLC types is called the 
TNM system, this stands for tumor (T), lymph nodes (N) and metastasis (M). SCLC is 
divided into two stages, limited stage where the tumor is limited to one lung and lymph 
glands in the centre of the chest or the root of the neck, and extensive stage where the 
tumor has spread beyond the lung it started in to more distant lymph glands or other organs 
in the body such as the liver or the brain (Gilligan and Rintoul, 2007; Mountain, 2008). 
 
1.1.6. Diagnosis and Treatment of LC:  
 Chest radiograph is the first diagnostic step for patients that have reported suspected 
symptoms of LC. This test may show some obvious mass, widening of the mediastinum, 
atelectasis, consolidation, or pleural effusion. CT imaging can provide more information 
about the type and extent of disease. Bronchoscopy or CT-guided biopsy is often used to 
sample the tumor for histopathology (Collins et al., 2007). 
LC is treated by surgery and adjuvant chemotherapy for early stage disease, concurrent 
chemoradiotherapy for locally advanced disease, and chemotherapy for metastatic disease 
(Pandya et al., 2007; Salgia and Skarin, 2012). Nevertheless treatment differs according to 
the histologic type of cancer, the stage at presentation, and the patient's functional 
evaluation (Collins, 2007; Salgia and Skarin, 2012). 
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1.1.7. Genetic Alterations in Lung Cancer: 
Lung tumorigenesis is a complex multi process that involves frequent genetic alterations 
that activate oncogenes and inactivate tumor suppressor genes (Devereux et al., 1996). 
Most, if not all, of these alterations are considered as being critical for changing the 
phenotype of non-cancerous cells or cancer cells to more malignant ones by stepwise 
progression. Thus, genetic alterations responsible for each step of phenotypic change in 
cancer cells can be considered as molecular footprints as long as the cells retain malignant 
phenotypes (Yokota et al., 2004). 
Genes involved in DNA repair, cell growth, signal transduction, and cell cycle control may 
all be damaged at different stages of lung tumor progression. Mutational activation of 
oncogenes, inactivation of tumor suppressor genes, and subsequent increased genetic 
instability are major genetic events in lung carcinogenesis (Yokota et al., 2004). 
 
1.1.7.1. Chromosomal Abnormalities: 
Non-random chromosomal abnormalities have been identified in LC cell lines and fresh 
tissues, including loss of chromosomes 3p, 9p, and 17p. Three distinct 3p regions may be 
affected, including 3p25, 3p21.3, and 3p14-cent. The loss of alleles at 3p is observed in 
greater than 90% of SCLC tumors and approximately 50% of NSCLC tumors (Salgia R et 
al., 2012). Initially, putative candidates on 3p included the c-RAF-1 proto-oncogene, the 
B-retnoic acid receptor gene, zinc finger containing genes, the protein tyrosine 
phosphatase-y gene, and the von Hippel Lindau tumor suppressor gene at 3p14-23. Most 
recently studied, the Fragile Histidine Triad (FHIT) gene localized to 3p14.2, and in one 
study approximately 80% of SCLC tumors showed abnormalities of this gene. Loss of the 
FHIT gene leads to the stimulation of DNA synthesis and proliferation (Sozzi et al., 1996). 
 
In NSCLC other genetic losses include genetic loss at chromosome 8p, which may occur in 
50% of tumor samples. Genetic loss at 9p involves the p16 and p15 tumor suppressor 
genes may occur in 67% of tumor samples. Genetic loss at 11p (p13 and p15) sometimes 
results in deletion of the Wilms' tumor suppressor gene at region p13 and may occur in 
20% to 46% of tumor samples (Salgia et al., 2012; Pandya et al., 2007).  
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Telomerase activity has been directly correlated with malignant and metastatic phenotype 
of a wide array of solid tumors, and many studies on LC tissues showed that most of the 
cases had high telomerase activity (Salgia R et al., 2012; Devereux TR et al., 1996).  
 
1.1.7.2.  Expression of Oncogenes: 
The most common oncogens that have been associated with LC include RAS, MYC, c-
erbB-2, and BCL-2. 
RAS. The rat sarcoma viral oncogene homolog (RAS) family of proto-oncogenes (KRAS, 
NRAS, and HRAS) encodes membrane-bound GTPases that play an important role in 
signal transduction and cellular proliferation. Ras is activated by point mutations in up to 
35% of LC, and is associated with smoking. Oncogenic mutations of KRas, commonly 
located in codons 12, 13, and 61, lead to increased GTP binding and constitutive activation 
of KRas and the MAP kinase pathway. Oncogeneic KRas is sufficient to expand murine 
bronchioalveolar stem cells in culture and in vivo (Pandya et al., 2007). 
 
MYC. The MYC dominant oncogenes, C-MYC (cellular), N-MYC (originally isolated 
from neuroblastoma cells), and L-MYC (originally isolated from SCLC cells), encode for 
nuclear DNA-binding proteins, which are involved in transcriptional regulation (Salgia et 
al., 2012). Amplification of MYC family proto-oncogenes is found in almost all small-cell 
lung cancers (SCLC) and is reported to confer an aggressive, resistant phenotype (Pandya 
et al., 2007). 
 
c-erbB-2. c-erbB-1 proto-oncogen encodes the epidermal growth factor receptor (EGFR) 
and has been a classic model for signal transduction events in normal and transformed 
cells. A related proto-oncogene, c-erbB-2 (also known as HER-2\neu) encodes for a 
protein product that is also a growth factor receptor (Salgia et al., 2012). Strong EGFR 
expression is present in 40% to 80% of NSCLC tumor specimens. High-level expression of 
EGFR is also present in premalignant bronchial epithelium, suggesting a role for EGFR in 
carcinogenesis (Pandya et al., 2007). 
 
BCL-2. BCL-2 is a negative regulator of cell death, prolongs the survival of noncycling 
cells, and inhibits apoptosis of cycling cells (Salgia et al., 2012).  
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1.1.7.3. Loss of Tumor Suppressor Genes: 
The most common tumor suppressor genes that have been associated with LC include RB, 
p53, and p16INK4A. 
RB. The RB gene encodes for a nuclear protein that was initially determined to be 
abnormal in patients with retinoblastoma. SCLC besides retinoblastoma was a tumor 
initially identified to have abnormalities of RB. In SCLC cell lines, there is rearrangement 
of chromosome 13, directly affecting the 13q14 locus where RB is located. Up to 70% of 
SCLC cell lines have alterations in RB gene or abnormal mRNA, which thereby leads to 
absent expression of the protein (Salgia et al., 2012). 
 
p53. The p53 tumor suppressor gene is the most commonly mutated gene in human cancer. 
The highest incidence of p53 mutations in lung cancer is in SCLC. Loss of p53 function or 
one of the genes in the p53 pathway of cellular growth control, can lead to unchecked 
progression of the cell cycle before appropriate DNA repair can occur (Salgia et al., 2012; 
Devereux et al., 1996). Although p53 alterations occur in the late stages of some cancers, 
they appear early in NSCLC suggesting that this gene may be damaged early in the genesis 
of LC and may provide a selective advantage for cell growth (Devereux et al., 1996). 
 
P16INK4A. Some LC specimens have deletion of chromosome 9p21, thus implicating one 
or more tumor suppressor genes in this region as being important, and from genetic 
analysis, p16INK4A has been identified to map within this region. Moreover, the 
expression of P16INK4A has been evaluated in LC cases (Salgia et al., 2012; Herbst et al., 
2008). 
 
1.1.8. Tumor Markers for Lung Cancer: 
Molecular markers are important tools for understanding the induction of cancer, early 
diagnosis, prognosis and identifying new treatment for cancer patients. They are non-
invasive, reproducible, and fast diagnostic tools in differential diagnosis and in monitoring 
therapy efficacy. Further research is necessary to uncover novel biomarkers that can help 
in the fight against cancer. The screening and investigation of their prognostic value is of 
great importance (Gilligan and Rintoul, 2007).  
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The determination of tumor markers at the time of primary diagnosis may be helpful 
because tumor markers expressed and released at the time of primary diagnosis are likely 
to be the most relevant markers for follow up monitoring. Moreover the rate and extent of 
decrease of preoperatively released markers after surgery provide useful information about 
remaining tumor burden and the effectiveness of therapy (Erbt et al., 1994). 
There are general tissue-based and serum-based tumor markers used for LC screening and 
diagnosis such as: 
 Neuron specific enolase (NSE). Numerous studies have supported its use in the diagnosis 
of SCLC. However, it does not have the sensitivity or specificity necessary for use in 
population screening (Shibayama T et al., 2001). 
 Carcinoembryonic antigen (CEA). Its levels are high in adenocarcinoma and large cell 
carcinoma, but the elevated levels are also detectable in various benign pathologies and 
other malignancies preclude its use in screening and limit its diagnostic use (Ebert W et al., 
1994). 
 Cytokeratin-19 fragments (CYFRA 21-1). It is the most sensitive tumor marker for 
NSCLC, particularly squamous cell tumors (Ebert W et al., 1994).  
 Progastrin- releasing peptide (ProGRP). It is a reliable marker for SCLC with good 
specificity and sensitivity. ProGRP has shown to be helpful in differential diagnosis, 
particularly in distinguishing SCLC from other LC types (Yamaguchi K et al., 1995, 
Stieber P et al.; Schalhorn A et al., 2001). 
 Squamous cell carcinoma antigen (SCCA). This marker has superior specificity for 
squamous cell cancer and can be used for histological subtyping (Ebert W et al., 1994). 
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1.2. Activation-induced Cytidine Deaminase (AID):  
  
1.2.1. The AID and APOBEC Family: 
APOBEC is the Apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like. It is a 
family of evolutionary conserved proteins that can insert mutations in DNA and RNA as a 
result of their ability to deaminate cytidine to uridine (Figure 1-b) (Holmes RK et al., 
2007). In humans, the APOBEC family consists of 11 members, including APOBEC1, 
APOBEC2, APOBEC3 (A-H), APOBEC4 and AID. All the APOBECs share the structural 
and catalytic backbone of the zinc-dependent deaminases, they have a zinc-coordination 
motif which forms the core of the catalytic site (Figure 1-a) (Larijani et al., 2012). 
 
Figure 1: The Human APOBEC Family of Proteins. (a) Domain organization of human 
APOBEC proteins. Red shading indicates the cytidine deaminase motifs in each protein; the 
consensus amino acid sequence is shown below. (b) The cytidine deamination reaction catalysed 
by APOBEC enzymes. In this process, cytidine is converted to uridine by the addition of water and 
the removal of an amine group (Holmes et al., 2007). 
 
Another member of the family, activation induced cytidine deaminase (AID), was 
discovered in 1999 by Muramatsu et al. AID is encoded by the Acida gene on chromosome 
12 (Revy et al., 2000). AID has been shown to be selectively expressed in germinal centers 
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of activated B cells (Revy et al., 2000). It is known to be a key molecule for generating 
'antibody memory' (Nagaoka et al., 2010), and essential for the antigen-driven 
diversification of immunoglobulin genes in the vertebrate adaptive immune system 
(Conicello, 2008). Genetic AID deficiency leads to Type 2 hyper-IgM syndrome, an 
immunodeficincey in which the inability to carry out class switch recombination leads to 
the absence of antibodies other than those of the IgM class (Conicello, 2008). AID 
deficiency has also been found to result in a range of other abnormalities such as 
autoimmunity and lymphoid hyperplasia (Meyers et al., 2011, Kuraok et al., 2011).  
Recently the tertiary structure of the human AID protein was modeled as shown in figure 
2. The model shows that AID protein has a core of 5 beta strands surrounded by 6 alpha 
helices with the Zn-coordinating residues (Larijani et al., 2012). 
 
Figure 2: The Three Dimensional Model of AID Protein. The left panel shows a ribbon model 
of the predicted structures of human AID. N- to C-terminus progression is shown in color from 
blue to red. The middle panel shows the putative catalytic (Zn- coordinating). The right panel 
shows a model of the surface topography of AID (Larijani et al., 2012). 
 
1.2.2.  Physiological Role of AID: 
Efficient humoral immunity to foreign antigens requires that mature B lymphocytes 
diversify their immunoglobulin genes through class-switch recombination (CSR) and 
somatic hypermutation (SHM). AID expressed mainly but not exclusively in activated 
mature B cells has an essential role in the induction of both CSR and SHM. During SHM, 
AID activity induces a very high rate of mutation of genes encoding the immunoglobulin 
heavy-chain and light-chain variable regions to generate immunoglobulins with greater 
antigen affinity (Lee-Theilen and Chaudhuri, 2010). AID has two separate functions in 
CSR; the DNA cleavage of target loci and the correct pairing of cleaved ends. The DNA 
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cleavage activity is localized to the N-terminal portion of AID protein, and the C-terminal 
portion of AID is responsible for appropriately pairing the cleaved DNA ends (Nagaoka et 
al., 2010). Although a lack of AID activity leads to immunodeficiency syndromes, higher 
AID expression results in malignant transformation of B cells and T cells as well as tumor 
development in various organs (lee-Theilen and Chaudhuri, 2010). 
1.2.3.  Pathological Role of AID in Cancer: 
AID was initially thought to be an RNA-editing enzyme, but the discovery that it could 
mutate E. coli DNA with a preference for targeting C nucleotides, provided insight into its 
mechanism of action (Honjo et al., 2002). The DNA deamination model proposes that AID 
binds to target DNA and deaminates dC to dU, thus creating a U-G mismatch. This triggers 
the base excision repair pathway, consisting of uracil DNA glycosylase (enzyme 
responsible for the removale of uracil in DNA, and acts downstream of AID) and apurinic-
apyrimidic endonuclease, followed by the activation of error-prone DNA repair pathways 
(Figure 3). On the other hand, the RNA editing hypothesis proposes that AID edits RNA, 
and the resultant product is involved in DNA cleavage at the target loci (Nagaoka et al., 
2010). It is clear that DNA-cleavage activity of AID does not have any specific recognition 
sequence because neither the V nor S region (regions on the DNA responsible for antibody 
diversity) contains any consensus cleavage site. In addition, no clear binding specificity of 
AID to DNA has been demonstrated (Robbiani et al., 2009). 
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Figure 3: Mechanism of Mutation Induction by AID Activity. AID deaminates cytosine (C), 
resulting in the generation of a uracil (U), and therefore can transform a DNA C:G pair into a U:G 
mismatch. (A) The AID-generated U:G mismatch can be recognized by uracil-DNA-glycosylase 
(UNG) or MSH2/MSH6 heterodimer and repaired correctly. (B) If DNA replication starts before 
recognition by the repair system, a U:G mismatch gives rise to C/G to T/A transition. Alternatively, 
(C) generation of an abasic site by UNG or (D) recognition of the U:G mismatch by the 
MSH2/MSH6 heterodimer induces any  mutations in the AID-generated U:G mismatch or at a 
nearby A:T site, respectively, in an error-prone manner (indicated as M) (Chiba T et al., 2012). 
 
Fortunately, AID activity is tightly regulated/ restricted to activated-normal B-lymphocytes 
and no activity is detected in normal tissues under normal physiologic conditions. However 
the role of AID as a DNA mutator enzyme led to the hypothesis that AID might induce 
inappropriate mutations in non-Ig genes. Evidence for this hypothesis came from a study 
on murine cell lines, the study showed that several genes e.g. myc, bc16, pim1, pax5 …etc 
are deaminated by AID and are repaired by mismatch and base excision repair pathways, 
but around 25% were not fully protected by the repair mechanisms and accumulated 
mutations (liu et al., 2008). 
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The generation of AID transgenic mice provided insight into the role of AID in 
tumorgenesis. Several reports on these transgenic mice showed that they develop 
lymphoma, gastric carcinoma, and hepatocellular carcinoma (Okazaki et al., 2003, 
Matsumoto et al., 2007, Takai et al., 2009). It has been proposed that AID expression 
persists in malignant B cells as well as in epithelial tumors and induce genomic instability 
and tumorgenesis by inserting mutation in tumor-related genes in both lymphoid and non 
lymphoid organs (Okazaki et al., 2003, Matsumoto et al., 2007, Takai et al., 2009). One of 
these genes which received great interest is p53, known as the "guardian of the genome". A 
report by Takai et al., showed that AID transgenic mice which developed hepatocellular 
carcinoma (HCC) had deleterious p53 mutations (Takai et al., 2009). AID-induced p53 
mutations were also reported in gastric epithelial cells (Matsumoto Y et al., 2007). 
Furthermore, somatic hypermutations in p53 gene were identified in B-cell chronic 
leukemia (Malcikova et al., 2008). These studies led to the conclusion that AID is an 
inducer of p53 mutagenesis in cancer cells (Takaishi et al., 2007). 
 
1.2.4.  Regulation of AID Expression: 
As a potent mutator, AID is under stringent transcriptional, post-transcriptional, and post-
translational regulation. Transcription factors such as HoxC4 an NF-ƙB which are 
upregulated in a B-cells upregulate the induction of AID (Xu et al., 2007). These 
transcription factors are triggered by several factors, some of which are pathogenic e.g. 
bacteria and viruses (Matsumoto et al., 2007; Endo et al., 2007). A report by Matsumoto et 
al., 2007 showed that Helicobacter pylori (H. pylori) infection caused AID-mediated p53 
mutations through an NF-ƙB activation pathway in gastric epithelial tissue. H. pylori 
introduces several bacterial virulence factors into gastric epithelial cells through a type-IV 
secretion apparatus, and this have been shown to be responsible for activating the 
transcription factor NF-ƙB and then induction of AID expression as shown in figure 4 
(Marusawa and Chiba , 2010). Other studies showed that AID is expressed in liver cancers 
and chronic hepatitis tissue. The introduction of the gene for the core protein of HCV into 
human hepatocyte induced AID expression via NF-ƙB activation. This is consistent with 
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previous studies showing that the core protein of HCV enhances NF-ƙB activation 
(Marusaua et al., 1999; Kou et al., 2006; Endo et al., 2007).  
  
Figure 4: H. pylori Infection Triggers AID Expression In Gastric Epithelial Cells Via Two 
Distinct Pathways (Marusawa and Chiba, 2010). 
 
It is well known that proinflammatory cytokine induction of AID expression via the NF-kB 
pathway is not limited to gastric epithelial cells. AID expression is mediated by the 
inflammatory response in a variety of epithelial cells, including human hepatocytes, and 
biliary and colonic epithelial cells. Aberrant AID expression in these gastrointestinal 
organs results in somatic mutations in various tumor-related genes. Thus, AID may have a 
central role in genetic susceptibility to mutagenesis, which leads to cancers in these 
gastrointestinal tissues upon exposure to certain inflammation or infection as shown in 
figure 5 (Marusawa and Chiba, 2010). 
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Figure 5: AID Links Inflammation and Infection to Cancer Development in Various 
Gastrointestinal Tissues (Marusawa and Chiba, 2010). 
 
AID promoter has also been shown to be triggered by the sex hormone estrogen; another 
transcriptional regulator. Estrogen-estrogen receptor complex was shown to bind to AID 
promoter enhancing AID's mRNA and protein levels an effect which was inhibited by 
tamoxifen; an estrogen antagonist. This study suggested clearly that estrogen- induced 
oncogenesis is derived through AID dependent mutagenesis (Paulkin et al., 2009). These 
findings might explain why women are more susceptible to autoimmune diseases and 
cancer particularly in breast tissue (Maul et al., 2009). 
AID undergoes a series of post-translational modification, such as nuclear/cytoplasmic 
translocation, dimerization/oligomerization, and phosphorylation, all of which play 
important roles in regulating AID activity and function in SHM and CSR (Xu et al., 2007). 
Many studies suggest that the subcellular localization of AID is tightly controlled to limit 
the amount of the enzyme in the nucleus (Delker et al., 2009), whereas the function of AID 
is exerted there, AID is predominantly cytoplasmic owing to the presence of a nuclear 
export signal (NES) at the extreme carboxyl termins (Conicello, 2008). 
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1.3. Objectives: 
Several studies showed aberrant AID protein expression in several types of cancer. In 
Palestine, link between cancer and AID, or other oncogenes or tumor suppressor genes is 
not studied yet. The aim of this study is to check if AID protein is expressed in LC 
Palestinian patients, and if AID protein level correlates with clinic-pathological data of the 
patient.   
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Chapter Two: Materials and Methods  
2.1. Materials: 
Reagents and buffers used in IHC and H&E staining are listed in table 1.  
Table 1: Materials for IHC and H&E Staining.  
Catalog #  Company  Material  
Cas #: 1330-20-7 Loba Chemie Xylene 
64-17-5 Carlo Erba Ethanol  
Ref#: 005000 Invitrogen Citrate buffer pH=6 
Article #: 194057  MP Biomedicals, USA  Hydrogen peroxide 3% 
00-8899 Invitrogen Pap-pen 
T5912-1L Sigma TBS buffer 
14-5959  e-Bioscience  Primary AID Ab  
00-8120 Invetrogen  Cass block  
414311F Histofine Secondary anti-Rat Ab 
957D-31  Cell -Marque DAB chromagen  
957D-32 Cell- Marque DAB buffer substrate 
GHS3128-4L Sigma Hematoxylene 
03989-10ML Fluka Mounting solution 
12-550-15 Fisher brand Super Frosted Plus slides 
E6003-25G Sigma  Eosin Y  
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2.2. Methods: 
  
2.2.1. Sample Collection: 
Archived paraffin embedded blocks of 63 LC cases were collected retrospectively for the 
last 11 years (from 2000-2011), from the Pathology Department at Al Maqassed Islamic 
Charitable Hospital in East Jerusalem. Cases were accompanied by their pathological 
reports obtained from the hospital's records archive. The data include age, gender, year of 
specimen collection, smoking status, tumor grade, and stage of tumor invasion. The study 
design proposal was approved by both the Faculty of Medicine, at Al-Quds University, and 
Al-Maqassed Islamic Charbitale Hospital. 
2.2.2. Tissue Sectioning: 
LC tissues taken from biopsy must be fixed using formalin, 10% neutral buffered formalin 
is most commonly used, and fixation between 18-24 hours, this was done be the technician 
in the Hospital's lab. Under fixation can lead to edge staining, with strong signal on the 
edges of the section and no signal on the middle, while over fixation can mask the epitope. 
Antigen retrieval can help overcome this masking, but if the tissue has been fixed for a 
long period of time, there may be no signal even after antigen retrieval. In this project, 2 
slides showed staining at the edges. Some negative cases may be occurred due to over 
fixation. After fixation tissue blocks must be embedded in paraffin wax and archived for 
further use. 
Tissue sections (5 µm thick slices), from archived paraffin embedded blocks, was cut using 
the microtome since it is the ideal thickness for IHC, and was mounted on super frosted 
plus glass slides. These slides electrostatically attract fresh frozen or formalin fixed 
paraffin embedded tissue sections. One section from each case block was prepared for 
H&E staining for histological diagnosis and evaluation, and one section for IHC staining.  
2.2.3. Standard Staining (H&E): 
For each case, standard H&E staining was performed for histological diagnosis and 
evaluation as shown in table 2 (Avwioro, 2011): 
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  Table 2: H&E Staining Protocol. 
Time Treatment 
2 min Xylene 1 
2 min Xylene 2 
1min Ethanol  100%  
1x5sec Ethanol  80% 
1x5sec Ethanol  70% 
3 min Tap water  
2-4 min Hematoxylin 
Wash  Tap water 
5-6 min Eosin  
3 min Tap water 
1x5sec Ethanol  70% 
1x5sec Ethanol  80% 
1 min  Ethanol  100% 
 Mounting solution and cover glass 
 
2.2.4. Immunohistochemistry (IHC): 
IHC has become a valuable tool in both diagnosis and research of infectious and neoplastic 
diseases in a variety of animals. The basis of IHC is very simple and bridges three 
scientific disciplines: immunology, histology and chemistry. The fundamental concept 
behind IHC is the demonstration of antigens (Ag) within tissue sections by means of 
specific antibodies (Ab). Once antigen-antibody (Ag-Ab) binding occurs, it is 
demonstrated with a colored histochemical reaction visible by light microscopy or 
flourochromes with ultraviolet light, and showing the localization of the antigen in the cell 
(Ramos-Vara, 2005).  
For cancer diagnosis, IHC represents an important complementary tool for the routine 
diagnosis of cancers including LC, and for the identification of the different histological 
types and prognostic factors. Its purpose is to categorize patients in order to ensure 
appropriate and specific treatment, as well as to identify tumors at higher risk of recurrence 
and fatal outcomes. It is better to perform RT-PCR with western blot and IHC for further 
confirmation, but this needs fresh tissue to be obtained from each case. IHC was performed 
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because of the availability of archived embedded blocks, and have an advantage of over 
Western Blott in that it shows the localization of the protein inside the cell, within the 
tissue. 
 All tissue sections mounted on superfrosted slides were treated according to the protocol 
of immunohistochemistry presented in table 3 (Ramos-Vara, 2005): 
 
Table 3: Immunohistochemistry Protocol. 
Notes Time Treatment 
Deparrafinization (in laminar flow hood) 3x3min Xylene  
To remove dissolved paraffin wax and 
Xylene 
3x1min Ethanol  
Hydration  3x1min Ethanol  96% 
Hydration  3min Ethanol  80% 
Wash  3x5sec DDW 
To enhance antigen exposure 15min, high 
power, in 
microwave 
Citrate buffer, pH6 
Wash  3x2min DDW 
Peroxidase quenching 15 min 3% hydrogen peroxide 
Wash  2x2min DDW 
Use Pap pen  Surround/circle the tissue 
 3x2 min TBS buffer 
Incubate at 4°C, diluted 1:50 Over night Primary AID Ab  
Wash  3x5 min TBS buffer  
2 drops 30 min Secondary Anti Rat-Ab 
Wash  3x5min TBS buffer  
"substrate chromagen" 25 min DAB chromagen  
Wash  5sec DDW 
Counter stain  45 sec Hematoxylene 
Wash  5sec Tap water 
Dehydrate  2min Ethanol 100% 
 2 min Xylene 1 
 2 min Xylene 2 
  Mounting solution and cover glass 
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 Control slides are important for accurate interpretation of results. There are two types of 
controls, positive control and negative control. Positive tissue control is a specimen, 
containing the antigen needed, processed at the same time with other slides, to insure that 
the conditions of the technique were performed accurately. Positive control slides were 
also used to detect the exact dilution needed for the primary antibody (i.e. for calibration) 
(Moldenhauer et al., 2006). For AID antibody the positive control used was sections from 
tonsil tissue kindly provided from Beit Jala Hospital. Tonsils as well as lymph nodes 
express high levels of cytoplasmic AID protein in B lymphocytes  
Negative control/ Reagent control is an additional slide, treated with a buffer instead of one 
step in the reaction, and processed at the same time with other tissues (Ramos-Vara, 2005). 
In this study, negative controls were treated with buffer instead of DAB chromagen. 
 Before proceeding with the staining protocol, the slides must be deparaffinized and 
rehydrated; incomplete removal of paraffin can cause poor staining of the sections. 
Therfore, xylene and graduated concentrations of ethanol were used. 
 
 When using a new antibody in IHC protocol, the antibody must be calibrated to find the 
optimal staining conditions. Each antigen has a preferred method of antigen retrieval, and 
each antibody has an optimal dilution. 
Most formalin fixed tissue requires an antigen retrieval step before immunohistochemical 
staining can proceed. This is due to the formation of methelyne bridges during fixation, 
which cross- link proteins and therefore masks antigenic sites. The two methods of antigen 
retrieval are heat-mediated antigen retrieval and enzymatic antigen retreival; in this 
experiment heat mediated antigen retrieval method was used; as described by previous 
reports (Greiner et al., 2005; Ghushima et al., 2010; Shinmura et al., 2011). This method is 
performed using a pressure cooker, microwave, or hot plate. In our experiment, IHC was 
performed using microwave. AID antigen was calibrated  by using different levels of 
power at different timing; at Mid power (10 min, 20 min), at Mid High power (10 min, 
20min), and at High power (10, 15, 20 min), and the perfect results obtained were at High 
power for 15 min. For performing heat induced antigen retrieval proper buffer should be 
calibrated, citrate buffer (pH=6) was used for this project as described in previous report 
(Greiner et al., 2005). 
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 In this project, monoclonal Anti-Human\Mouse Activation Induced Cytidine Deaminase 
(AID) was used, it recognizes human and mouse AID. Calibration for the accurate dilution 
of the AID Ab was done by using different buffer concentrations. We have used Ab:cass 
block concentration of 1:50, 1:100, 1:200. The optimum staining result was obtained by the 
dilution 1:50. Cass block is a universal blocking agent for reducing nonspecific 
background staining in immunolableing techniques, and works well as a diluting reagent 
for primary Abs. Slides were incubated with primary Ab for one hour at room T, and 
overnight at 4 C, the best results obtained by overnight incubation. 
 Slides were treated with hydrogen peroxide (H2O2), for blocking endogenous peroxidase 
activity which may lead to false positive results, since we are using DAB as a substrate for 
peroxidase enzyme labeled on the secondary Ab. We have used control slides at different 
(H2O2) timing; 10 min and 15 but the results were not different. 
 
 The secondary Ab used is labled with horse radish peroxidase (HRP), and DAB substrate 
chromagen is suitable for use with HRP detection system; it enables the antibody antigen 
complex to be viewed under the light microscope, this occurs because DAB acts as an 
electron donor in the presence of the HRP, DAB gets reduced and the color change to 
brown. Slides were incubated with DAB at different timing; 5 min, 10 min, 15 min, 20 
min, 25 min, and the best results obtained at 25 min. 
 
 Evaluation of AID protein expression, within the slides was supervised by the pathologist 
Dr. Riyad Shreim, and the intensity of cytoplasmic expression classified according to the 
three grade scale (0: no staining; 1+: weak positive staining, +2 strong positive staining)  
(Gushima et al., 2011). 
 
2.2.5. Statistical Analysis: 
 
Statistical analysis was performed to find if there is a significant correlation between AID 
protein expression and clinic-pathological data of the cases. Pearson's chi-squared test 
was used, and converted to P-value. P-value <0.05 was considered to be statically 
significant. 
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Chapter Three: Results 
 
3.1. Study Samples: 
 
The general clinical and pathological data of LC cases are summarized in Table 4; this 
includes age, gender, smoking status, LC type, and tumor grade. These data were 
organized randomly. 
As shown in Table 4, IHC was performed for 58 LC cases and one normal lung sample, 
and for further confirmation, a whole set of slides (8 cases) chosen randomly, were 
repeated IHC with similar results. 
 
Table 4: Clinico-pathological Data &AID Expression for the LC Cases. 
 
AID 
Exp.
 
Tumor grade  
 
LC type  
Smoki
-ng 
status 
 
Sex  
 
Age  
 
Block  # 
 
S.
# 
+1 Moderately d.  Squamous cc - M 50 1655-09 IE 1.1 
0 Moderately d. Squamous cc S M 51 728-07 2. 
+1 Moderately d. Squamous cc - M 53 1873-08 3. 
0 Moderately d. Adenocarcinoma  S M 50 1049-07 H 4. 
0 Moderately d. Squamous cc NS F 39 968-09 5. 
0 Moderately d.  Adenocarcinoma  NS F 68 59-09 6. 
0 Moderately d.  Squamous cc S M 74 1304-08 7. 
0 Moderately d. Adenocarcinoma. S M 42 822-04 8. 
0 Moderately d. Squamous cc S M 78 835-08 9. 
0 Poorly d. Squamous cc - M 63 2047-09 10. 
0 Poorly d. Squamous cc S M 61 1088-07 11. 
0 Poorly d. Squamous cc NS M 60 743-10 12. 
0 Moderately d. Adenocarcinoma  NS M 76 1432-01 13. 
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0 Moderately d. Adenocarcinoma  S M 38 33-06 II 14. 
0 Moderately d. Adenocarcinoma  S M 49 1046-03 15. 
0 Moderately d. Adenocarcinoma S M 75 48-08 16. 
0 Poorly d. Adenocarcinoma - M 78 596-10 II 17. 
0 Moderately d. Squamous cc NS M 69 2764-01 18. 
0 Moderately d.  Squamous cc - M 61 1995-09 IJ 19. 
0 Moderately d. Adenocarcinoma S M 75 585-10 I 20. 
0 Poorly d. Squamous cc NS F 40 517-05 21. 
0 Moderately d. Adenocarcinoma  S M 46 871-07 22. 
0 Poorly d. Adenocarcinoma S M 63 728-03 IIA 23. 
0 Poorly d. Adenocarcinoma - F 69 2185-11 II 24. 
0 Poorly d. Adenocarcinoma - M 64 1361-11 I 25. 
0 Moderately d.  Squamous cc S M 65 1848-11 I 26. 
0 Moderately d. Adenocarcinoma  - M 51 1245-11 I 27. 
0 Moderately d.  Adenocarcinoma - M 50 1673-11 28. 
0 Poorly d. Squamous cc  S M 52 2331-11 I 29. 
0 Poorly d.  Squamous cc - M 65 2449-11 IE 30. 
0 Poorly d. Squamous cc - M 68 1188-11 31. 
+1 Poorly d.  Squamous cc - M 65 2449-11 IC 32. 
0 Moderately d. Adenocarcinoma - M 51 1245-11 IIA 33. 
+1 Poorly d. Adenocarcinoma  - F 69 2185-11 I 34. 
+1 Poorly d. SCLC - M 62 2061-11 35. 
0 Well d. Squamous cc - M 50 2861-10 A 36. 
+1 Poorly d. Adenocarcinoma  - M 78 1698-10 37. 
0 Poorly d. Squamous cc  - M 80 1700-10 I 38. 
0 Poorly d. Adenocarcinoma  - M 78 596-10 I 39. 
+1 Poorly d. SCLC - F 61 1245-10 40. 
0 Moderately d. Squamous cc - F 73 1310-10 41. 
0 Moderately d.  Squamous cc - M 57 1423-10 42. 
0 Moderately d. Adenocarcinoma - F 42 1913-10 43. 
0 Poorly d. Adenocarcinoma - F 59 2837-10 C 44. 
0 Poorly d. Squamous cc - M 70 1359-10 A 45. 
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0 Moderately d.  Squamous cc - M 66 1636-10 II 46. 
+1 Moderately d. Squamous cc - M 47 1479-08 47. 
+1 Poorly d. SCLC - M 34 1726-092 48. 
+1 Poorly d. Adenocarcinoma - F 42 1247-08 49. 
0 Moderately d. Squamous cc  - M 61 1995-9 IA 50. 
0 Moderately d. Squamous cc S M 60 761-09 51. 
0 Poorly d. Adenocarcinoma  - M 62 1230-08 52. 
+1 Moderately d. Squamous cc - M 50 1655-9 IB 53. 
+1 Poorly d. Squamous cc S M 74 1304-8 E 54. 
0 Moderately d. Squamous cc - M 62 1639-8 55. 
0 Moderately d. Squamous cc - M 61 1995-9 II 56. 
+1 Moderately d. Squamous cc - M 74 1306-8 57. 
0 Moderately d. Adenocarcinoma - F 69 1647-09 58. 
0 - - - - - Normal L. * 
M: male, F: female, S: smoker, NS: nonsmoker. 
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3.2 Summary of the Clinico-Pathological Data of the LC 
Cases: 
 
As shown in table 5; 81% of the patients were males and 19% were females. The age of the 
patient's ranges between 34 years and 80 years, the average was (55 years). The table also 
shows the smoking status of some patients; 16 patients were smokers, and 6 patients were 
nonsmokers. 
As for LC staging the table shows that 95% were NSCLC [among them (44% 
adenocarcinoma, and 56% squamous cell carcinoma], and 5% were SCLC, this is 
agreement with other studies showing that NSCLC is the most common LC type. As for 
tumor grade, 41% were poorly differentiated, 57% were moderately differentiated, and 2% 
were well differentiated. 
 
Table 5: Summary of the Clinico-pathological Data of  LC Cases. 
Patient characteristics:  Frequency (%) 
 
Gender 
 
Male  
Female  
 
47 (81%) 
11 (19%) 
 
 
Age  
 
Range 
>=60 
<60 
Average 
 
34-80 
36 (62%) 
22 (38%) 
55 
 
Smoking: 
 
Among Documented:
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 Smoker  
Non smoker  
16 
6 
 
 
LC type: 
 
 
NSCLC: 
Squa   
Adeno  
 
SCLC: 
 
55 (95%) 
31 (56% of NSCLC) 
24 (44% of NSCLC) 
 
3 (5%) 
 
Tumor Grade: 
 
 
Poor d 
Mod d 
Well d 
 
24 (41%) 
33 (57%) 
1 (2%) 
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3.3  IHC Evaluation and Statistical Analysis of the LC cases: 
 
Positive controls (tonsils tissue sections), were stained in brown with cytoplasmic 
localization (Figure 6-a), and negative controls were not stained (Figure 6-b). 
  
Figure 6: Cytoplasmic AID Expression in Positive Control (a), and Negative Control 
(b), at 10x magnification. 
 
 
 
 
 
AID protein expression was detected in 22.4% (13 of 58) of cases with cytoplasmic 
localization, No expression was revealed in normal lung tissue (Figure 7-a) or in 77.5% (45 
of 58) of the cases including squamous cell carcinoma and adenocarcinoma (Figure 7-b, 7-
c, respectively). 
 
Figure 7: Negative AID Expression in Normal lung Tissue (a), Squamous cc (b), and 
Adenocarcinoma (c), at 10x magnification.  
 
 
 
 
a  b 
b c a  
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As shown in table 6, 18% (10 of 55) of NSCLC, and 100% (3 of 3) of SCLC (Figure 8-a) 
were positive cases. Among NSCLC, 23% (7 of 31) of squamous cell carcinoma (Figure 8-
b), and 13% (3 of 24) of adenocarcinoma (Figure 8-c) were positive. No significant 
difference was found between LC types (P=0.9985), or subtypes (P=0.5621, not shown in 
the table). 
 
Figure 8: Positive AID Expression in SCLC (a), Squamous cc (b), Adenocarcinoma 
(c), at 10x magnification. 
 
 
 
  
 
Table 6 shows that; 15%, and 33% of , moderately, and poorly differentiated; show AID 
protein positive, respectively, and no AID protein expression in well differentiated cases. 
No significant difference was found between LC tumor grade (P=0.7240). The table also 
shows that; 21% of males and 27% of females were positive cases, and no significant 
difference was found between gender (P=0.4137), and the table shows that 19% of the 
positive cases were over or equal 60 years, and 27% were below 60 years, and no 
significant difference was found between the two groups of age (P= 0.4848). Since most of 
the cases did not have complete clinical data concerning smoking status, percentage among 
positive cases or correlation with AID protein expression could not be detected. 
 
 
 
 
 
 
 
 
ba  c 
 30
Table 6: Correlation between AID Protein Expression and Clinico-pathological 
Parameters. 
 
Variable\AID 
 
0 
 
+1 
 
Total  
% of AID 
positive 
cases 
 
χ2 
 
P value  
    0.668 0.4137 
37 10 47 21%   
Gender  
M  
F 8 3 11 27%   
    0.488 0.4848 
29 7 36 19%   
Age  
>=60 
<60 16 6 22 27%   
    0.003 0.9985 
45 10 55 18%   
21 3 24 13%   
24 7 31 23%   
LC type 
NSCLC 
Adenocarcinoma 
Squamous cc 
       SCLC 0 3 3 100%   
    0.646 0.7240 
1 0 1 0%   
28 5 33 15%   
Tumor grade 
Well d. 
Moderately d 
Poorly d. 16 8 24 33%   
 χ2: Chi square test. 
 P value ≤0.05, AID protein expression versus clinico‐pathological parameters. 
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Discussion 
 
Activation induced cytidine deaminase (AID), is expressed in activated B cells and is 
involved in antibody diversification by inducing mutations immunoglobulin genes (Revy et 
al., 2000). AID has been shown to attack non-immunoglobulin genes and induce mutations 
broadly throughout the genome in B cells (Nogaoka et al., 2010). Aberrant AID expression 
can induce mutations in fibroblasts, and the constitutive expression of AID in mice causes 
not only lymphomas, but also cancers of other organs including the lung, suggesting that 
ectopically expressed AID has an oncogenic potential via its mutagenic activity (Okazaki 
2003). In accordance several studies has been reported that AID is aberrantly expressed in 
several cancer types such as gastric carcinoma (Matsumoto et al., 2007), hepatocellular 
carcinoma (Takai 2009), lymphoma and leukemia (Klemm et al., 2009), Hodgkin 
lymphoma (Greiner et al., 2005), esophageal squamous cell carcinoma (Zhang et al., 
2011), colitis associated colorectal cancer (Endo et al., 2008), and lung cancer (Shinmura 
et al., 2011).  
A recent study by Shinmura et al 2011, reported for the first time, the aberrant AID 
expression in human LC. This study showed aberrant mRNA expression of AID in 29% (5 
of 17) of the LC cell lines and 31% (16 of 51) of the primary LC. However, this aberrant 
AID mRNA expression didn’t show any association with the clinico-pathological factors 
such as age, gender, smoking history, tumor stage, or tumor histology. As for AID protein 
expression, analysis revealed that AID protein expression was mostly cytoplasmic with a 
small portion of AID localized at the centrosomes (Shimura et al., 2011). No association 
was detected between AID protein expression level and the clinicopathological factors 
such as gender or tumor histology. Furthermore, an association was found between the 
AID protein expression level and the p53 mutation status in an analysis of 129 primary LC. 
When LC cases were divided into NSCLC and SCLC, an association between the p53 
mutation status and AID protein expression level was also detected in NSCLC (Shinmura 
et al., 2011). 
In the present study, we examined the expression of AID protein in LC tissue sections 
derived from Palestinian patients' paraffin embedded blocks. AID signal was mainly 
observed in the cytoplasm in accordance with previous studies (Shinmura et al., 2011; Kou 
et al., 2006; Endo et al., 2008; Zhang et al., 2011). Results revealed that AID protein is 
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overexpressed in 21% of LC cases. In particular 20% (10 of 50) of NSCLC and 100% (3 of 
3) of SCLC express AID protein. Among NSCLC 29% of squamous cell carcinoma, 13% 
of adenocarcinoma, and 0% of large cell carcinoma express AID protein. Our results are 
consistent with the study of Shinmura et al showing AID protein expression in 35.7% (46 
of 129) of the cases (Shinmura et al., 2011). Interestingly, SCLC cases examined by 
Shinmura showed expression in 40.0% (4 of 10) of the cases while our results in 
Palestinian cases of SCLC showed 100% (3 of 3). Protein level of AID was not detected in 
normal lung tissue, because AID is not expressed under physiological conditions in normal 
tissues other than tonsils or lymph nodes; where it functions in CSR and SHM (Meyers et 
al., 2011). In our results correlation between AID protein expression and clinic-
pathological parameters; age, sex, LC type, tumor grade, was not detected. 
To explain the tumorgenic activity of AID among these patients, other experiments should 
be performed, examining regulation of AID and its tumorgenic effect inducing mutations 
in tumor suppressor genes or oncogenes. AID is regulated by several factors; AID 
promoter includes sites for the transcription factors NFkB, STAT6, HoxC4, Sp1 and Pax5 
(Delker 2009). Several factors can influence and trigger NFkB, which is a major activator 
of AID expression. As a major cell survival signal, NFkB is involved in multiple-steps in 
carcinogenesis (Chen et al., 2012). Recent studies showed that NF-kappaB is constitutively 
activated in a variety of solid tumors, including prostate, breast, cervical, pancreatic and 
lung cancer (Chen et al., 2012). Tumor samples obtained from lung cancer patients showed 
high levels of NF-kappaB activation in both (SCLC) and (NSCLC) (Chen et al., 2012). A 
large body of evidence suggests that inflammation plays an important role in lung cancer 
development (Chen et al., 2012). Exposure to asbestos is associated with the development 
of pulmonary fibrosis, and lung carcinogenesis (Janseen et al., 1995). Several studies 
showed that NF-kB is induced by asbestos, and this is a key event in regulation of multiple 
genes involved in the pathogenesis of asbestos related LC (Janseen et al., 1995).  
Cigarette smoke (CS) is a common cause of chronic lung inflammation (Anand et al., 
2003). Myeloid cells (mainly macrophages) are the major source of inflammatory 
cytokines for cancer promotion and progression (Anand et al., 2003).  NF-kappaB is a 
major signal in mediating cytokine synthesis and secretion from myeloid cells. Thus, it is 
suggested that NF-kappaB in myeloid cells promotes lung cancer mainly through 
mediating inflammatory cytokines secretion to establish a cancer-prone inflammatory 
microenvironment (Anand et al., 2003). In addition, NF-kappaB in epithelial cells also 
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plays a lung cancer-promoting role (Anand et al., 2003). NF-kappaB has been shown to be 
activated by cigarette smoke (CS) in a panel of NSCLC cell lines (Anand et al., 2003). 
Because NF-kappaB is persistently activated by CS in the lung epithelial cells far before 
tumor formation, it is likely that this cell survival signal promotes mutant cells to 
proliferate and to escape apoptosis in the early phase of lung cancer development (Chen et 
al., 2012). Further studies on this issue should provide us with more information regarding 
possible activation of AID by NFkB in LC.  
Several studies showed that AID induces genomic instability and tumorgenesis by 
inserting mutations in tumor related genes in both lymphoid and non-lymphoid organs. 
Study on murine cell lines showed several genes e.g. myc, bc16, pim1 pax5 and others are 
deaminated by AID (liu et al., 2008). AID-induced p53 mutations were reported in 
hepatocarcinogenesis (Takai et al., 2009), gastric epithelial cells (Matsumoto et al., 2007), 
B cell chronic leukemia (Malickova et al., 2008), and LC (Shinmura et al., 2011).  
Mutational activation of oncogenes and inactivation of tumor suppressor genes and 
subsequent increased genetic instability are major genetic events in lung carcinogenesis. 
KRAS mutations occur primarly in adenocarcinoma and are seen at a much lower 
frequency in non-smokers (5%) than in smokers (30%). P53, RB1 and P16 mutations and 
inactivation have the same frequency in adenocarcinoma as in squamous cell carcinoma. 
Squamous cell carcinomas show high frequency of p53 mutations. SCLC shows aggressive 
behavior and poor prognosis, and has a strong relationship to cigarette smoking; only about 
1% occurs in non-smokers. P53 and RB1 tumor suppressor genes are frequently mutated in 
50% to 80% and 80% to 100% of SCLC, respectively (Robbins and Cotran, 2010)  
In this study a possible suggestion for AID activation in these LC cases is that cigarette 
smoke may induce NFkB and this in turn binds to the promoter of AID and induces its 
expression. Activated AID induces mutations in tumor suppressor genes and oncogenes. 
Further studies are needed to verify this hypothesis; figure 9 suggests a possible 
mechanism for the pathway of AID induction in LC cells. 
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Figure 9: Proposed Mechanism of AID Induction in LC through NF-kB Activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In conclusion, our findings show the aberrant expression of AID may be involved in a 
subset of LC patients, with variations from one type to another. No correlation was 
detected between AID expression and age, gender, LC type or tumor grade. More studies 
are needed to shed the light on AID induction, mechanism of action, regulation and 
possible targets within LC. 
NF‐KB
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AID protein 
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Recommendations 
To enable the researcher to study AID expression and correlation with clinico-pathological 
data provided in a large cohort of patients, more cases of LC types and subtypes will be 
examined for AID expression. 
A major problem in clinical research in Palestine is the insufficient clinical data in the 
patient's files which makes the statistical analysis of the data for clinical research 
inadequate.  
IHC technique will performed with other techniques for further confirmation, such as RT-
PCR, western blott, and this requires fresh tissue to be obtained from patients, so 
cooperation with researchers at the hospitals is of great importance. 
I recommend in the future that the oncologist, pathologist and molecular biologist, 
contribute from the start of the project to obtain samples and full clinical information 
needed for the project.  
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ﻋﻨﺪ  ( esanimaeD enidityc-decudni noitavitcA)ﻓﺤﺺ ﻣﺴﺘﻮى اﻟﺒﺮوﺗﻴﻦ 
 ﻣﺮﺿﻰ ﺳﺮﻃﺎن اﻟﺮﺋﺔ
 
  آﻮﺛﺮ ﻋﻠﻲ اﻟﻘﻀﻤﺎﻧﻲ: اﻋﺪاد اﻟﻄﺎﻟﺒﺔ
  
  روﻻ ﻋﺒﺪ اﻟﺴﻼم ﻋﺒﺪ اﻟﻐﻨﻲ: اﺷﺮاف اﻟﺪآﺘﻮرة
  
وهﻮ اﻟﺴﺒﺐ ,  آﻞ ﻋﺎمﻓﻬﻮ ﻳﺼﻴﺐ اآﺜﺮ ﻣﻦ ﻣﻠﻴﻮن ﻣﺮﻳﺾ, ﺳﺮﻃﺎن اﻟﺮﺋﺔ هﻮ ﻣﻦ اآﺜﺮ اﻧﻮاع اﻟﺴﺮﻃﺎن اﻟﺸﺎﺋﻌﺔ ﻓﻲ اﻟﻌﺎﻟﻢ
, 6002وﺑﻨﺎء ﻋﻠﻰ اﺣﺼﺎﺋﻴﺎت وزارة اﻟﺼﺤﺔ ﻟﻌﺎم . ﻓﻲ ﻓﻠﺴﻄﻴﻦ,  اﻟﻤﺘﻌﻠﻘﺔ ﺑﺎﻻﺻﺎﺑﺔ ﺑﻤﺮض اﻟﺴﺮﻃﺎنﻴﺎتاﻟﺮﺋﻴﺴﻲ ﻟﻠﻮﻓ
و ﻳﺤﺘﻞ اﻟﻤﺮﺗﺒﺔ اﻻوﻟﻰ ﻣﻦ ﺣﻴﺚ ﻋﺪد , ﻓﺎن ﺳﺮﻃﺎن اﻟﺮﺋﺔ ﻳﺤﺘﻞ اﻟﻤﺮﺗﺒﺔ اﻟﺮاﺑﻌﺔ ﻣﻦ ﺣﻴﺚ ﻋﺪد اﻻﺷﺨﺎص اﻟﻤﺼﺎﺑﻴﻦ
  .اﻟﻮﻓﻴﺎت ﻓﻲ اﻟﻤﺠﺘﻤﻊ آﻜﻞ
  
و . ﻠﻌﺐ دورا ﻣﻬﻤﺎ ﻓﻲ ﻋﻤﻠﻴﺔ اﻟﻤﻨﺎﻋﺔ و ﺑﻨﺎء اﻻﺟﺴﺎم اﻟﻤﻀﺎدة ﻳ)CEBOPA(ﻣﻦ ﻋﺎﺋﻠﺔ اﻧﺰﻳﻤﺎت ال , )DIA(اﻟﺒﺮوﺗﻴﻦ 
اﻻ اﻧﻪ ﻗﺪ , ﺑﺎﻟﺮﻏﻢ ﻣﻦ ان اﻻهﺪاف اﻟﻔﺴﻴﻮﻟﻮﺟﻴﺔ ﻟﻬﺬا اﻟﺒﺮوﺗﻴﻦ هﻲ اﻟﺠﻴﻨﺎت اﻟﻤﺘﻌﻠﻘﺔ ﺑﺎﻻﺟﺴﺎم اﻟﻤﻀﺎدة ﻓﻲ ﺟﻬﺎز اﻟﻤﻨﺎﻋﺔ
ة ﺑﻴﻦ ارﺗﻔﺎع ﻣﺴﺘﻮى وﻗﺪ اﺛﺒﺘﺖ دراﺳﺎت آﺜﻴﺮة اﻟﻌﻼﻗﺔ اﻟﻜﺒﻴﺮ. ﻳﺴﺘﻬﺪف ﺟﻴﻨﺎت اﺧﺮى ﺗﻠﻌﺐ دورا ﻣﻬﻤﺎ ﻓﻲ ﻧﺸﺄة اﻟﺴﺮﻃﺎن
اﻻﻣﻌﺎء و اﻟﻜﺒﺪ و و اﻟﺘﻬﺎب اﻟﻘﻮﻟﻮن , اﻟﺜﺪي, آﺴﺮﻃﺎن اﻟﻤﻌﺪة, هﺬا اﻟﺒﺮوﺗﻴﻦ ﻓﻲ اﻟﺨﻼﻳﺎ و اﻧﻮاع ﻣﺘﻌﺪدة ﻣﻦ اﻟﺴﺮﻃﺎن
  .اﻟﺘﻘﺮﺣﻲ و ﻏﻴﺮهﺎ
  
و ﻟﺘﺤﻘﻴﻖ هﺬﻩ اﻻهﺪاف ﻗﻤﻨﺎ , هﻮ ﻓﺤﺺ ﻣﺴﺘﻮى هﺬا اﻟﺒﺮوﺗﻴﻦ ﻓﻲ ﻋﻴﻨﺎت ﻟﻤﺮﺿﻰ ﺳﺮﻃﺎن اﻟﺮﺋﺔ, اﻟﻬﺪف ﻣﻦ هﺬﻩ اﻟﺪراﺳﺔ
ﺧﻼل اﻟﺴﻨﻮات اﻟﻌﺸﺮ اﻻﺧﻴﺮة ﻣﻦ ﻋﺎم ,  ﻣﺮﻳﺾ ﺑﺴﺮﻃﺎن اﻟﺮﺋﺔ ﻣﻦ ﻣﺴﺘﺸﻔﻰ اﻟﻤﻘﺎﺻﺪ اﻟﺨﻴﺮي ﺑﺎﻟﻘﺪس85ت ﺑﺠﻤﻊ ﻋﻴﻨﺎ
  .yrtsimehcotsihonummI  ﻣﻦ ﺧﻼل ﺗﺠﺮﺑﺔ ال  )DIA(  وﻗﻤﻨﺎ ﺑﻔﺤﺺ ﻣﺴﺘﻮى اﻟﺒﺮوﺗﻴﻦ1102-0002
  
و اﻧﻪ ﻣﻮﺟﻮد . ﺤﺼﻬﻢﻣﻦ ﻣﺮﺿﻰ ﺳﺮﻃﺎن اﻟﺮﺋﺔ اﻟﺬﻳﻦ ﻗﻤﻨﺎ ﺑﻔ% 12 ﻣﻮﺟﻮد ﻋﻨﺪ DIA وﻗﺪ اﻇﻬﺮت اﻟﻨﺘﺎﺋﺞ ان اﻟﺒﺮوﺗﻴﻦ 
و اﻇﻬﺮت اﻟﻨﺘﺎﺋﺞ اﻻﺣﺼﺎﺋﻴﺔ (. CLCS)ﻋﻨﺪ ﻧﻮع % 001و ﺑﻨﺴﺒﺔ , (CLCSN)ﻋﻨﺪ اﻟﻤﺮﺿﻰ ﻣﻦ ﻧﻮع % 52ﺑﻨﺴﺒﺔ 
ﻋﺪم و ﺟﻮد ﻋﻼﻗﺔ ﺑﻴﻦ ﻣﺴﺘﻮى هﺬا اﻟﺒﺮوﺗﻴﻦ ﻣﻊ اﻟﻤﺘﻐﻴﺮات اﻟﻄﺒﻴﺔ ﻟﻠﻤﺮﺿﻰ ﻣﺜﻞ اﻟﻌﻤﺮ و اﻟﺠﻨﺲ و ﻧﻮع ﺳﺮﻃﺎن اﻟﺮﺋﺔ و 
  .  ﻟﻠﺒﺤﺚ اﻟﻌﻠﻤﻲ ﻓﻲ ﻣﺠﺎل ﺳﺮﻃﺎن اﻟﺮﺋﺔ ﻟﺪى اﻟﻤﺮﺿﻰ اﻟﻔﻠﺴﻄﻴﻨﻴﻴﻦﻣﺴﺘﻮى اﻟﻤﺮض و هﺬﻩ اﻟﻨﺘﺎﺋﺞ ﺗﻔﺘﺢ اﺑﻮاب ﺟﺪﻳﺪة
 
 
